A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-01-04
DOI
10.1038/s41598-017-18555-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of exercise training on sleep apnoea in patients with coronary artery disease: a randomised trial
- (2016) Monique Mendelson et al. EUROPEAN RESPIRATORY JOURNAL
- Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
- (2016) Paul F Mercer et al. THORAX
- αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease
- (2015) Gauri Saini et al. EUROPEAN RESPIRATORY JOURNAL
- Lipoxin A4Attenuates Constitutive and TGF-β1–Dependent Profibrotic Activity in Human Lung Myofibroblasts
- (2015) Katy M. Roach et al. JOURNAL OF IMMUNOLOGY
- The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis
- (2014) James D. Williamson et al. EXPERIMENTAL LUNG RESEARCH
- Endogenously Expressed IL-13R 2 Attenuates IL-13-Mediated Responses but Does Not Activate Signaling in Human Lung Fibroblasts
- (2014) S. Chandriani et al. JOURNAL OF IMMUNOLOGY
- A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
- (2014) Talmadge E. King et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
- (2014) Luca Richeldi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The K+ Channel KCa3.1 as a Novel Target for Idiopathic Pulmonary Fibrosis
- (2014) Katy Morgan Roach et al. PLoS One
- Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis
- (2014) Daryle J DePianto et al. THORAX
- Lack of specificity of fibroblast-specific protein 1 in cardiac remodeling and fibrosis
- (2013) Ping Kong et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Steroids in Idiopathic Pulmonary Fibrosis Acute Exacerbation: Defenders or Killers?
- (2013) Spyros A. Papiris et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Blockade of KCa3.1 Ameliorates Renal Fibrosis Through the TGF-β1/Smad Pathway in Diabetic Mice
- (2013) Chunling Huang et al. DIABETES
- Ex vivo culture of human prostate tissue and drug development
- (2013) Margaret M. Centenera et al. Nature Reviews Urology
- NICE guidance on pirfenidone for treating idiopathic pulmonary fibrosis
- (2013) Linda J Landells et al. Lancet Respiratory Medicine
- Ca2+-Activated K+Channel–3.1 Blocker TRAM-34 Attenuates Airway Remodeling and Eosinophilia in a Murine Asthma Model
- (2012) Pierre-Olivier Girodet et al. AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary Fibrosis
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Precision cut lung slices as an efficient tool for in vitro lung physio-pharmacotoxicology studies
- (2012) Jean-Paul Morin et al. XENOBIOTICA
- Matrix Metalloproteinase 3 Is a Mediator of Pulmonary Fibrosis
- (2011) Cory M. Yamashita et al. AMERICAN JOURNAL OF PATHOLOGY
- Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma
- (2011) Aarti Shikotra et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The rising incidence of idiopathic pulmonary fibrosis in the UK
- (2011) V. Navaratnam et al. THORAX
- Therapeutic potential of KCa3.1 blockers: recent advances and promising trends
- (2010) Heike Wulff et al. Expert Review of Clinical Pharmacology
- Role of integrin-mediated TGFβ activation in the pathogenesis of pulmonary fibrosis
- (2009) Amanda Goodwin et al. BIOCHEMICAL SOCIETY TRANSACTIONS
- Recent Advances in Molecular Targets and Treatment of Idiopathic Pulmonary Fibrosis: Focus on TGFβ Signaling and the Myofibroblast
- (2009) M. Gharaee-Kermani et al. CURRENT MEDICINAL CHEMISTRY
- Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels
- (2009) I. Grgic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia
- (2008) K. I. Ataga et al. BLOOD
- The bleomycin animal model: A useful tool to investigate treatment options for idiopathic pulmonary fibrosis?
- (2007) Antje Moeller et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation